MSD takes a $400m bite of SciBrunch's KRAS drug
MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
Roche culls myostatin candidate from obesity pipeline
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Test could end uncertainty in inherited muscle diseases
A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
AbbVie's Cerevel takeover delivers Parkinson's approval
The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
MSD, Daiichi pull filing for lung cancer candidate I-DXd
MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Why Join The PM Society?
The professional organisation for people working in pharmaceutical marketing and healthcare communications, and why it's worth being part of.
Six Questions Shaping the Future of Health Innovation
The DIA-MHRA Global Summit explores six questions shaping the next decade of health innovation.
PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.